[
  {
    "ts": null,
    "headline": "Why Organon Is A Top Pick For Income Investors",
    "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
    "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742252303,
      "headline": "Why Organon Is A Top Pick For Income Investors",
      "id": 133211092,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472143072/image_1472143072.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
      "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider",
    "summary": "The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=39a7526e301ae46718f93ca90446d42e78c0cf2243de614387f1f7b888401add",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742248814,
      "headline": "Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider",
      "id": 133325064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=39a7526e301ae46718f93ca90446d42e78c0cf2243de614387f1f7b888401add"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b84354278886d46450c4886dc57317fd75b574e723fd3f35db099d58b77c4635",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742229240,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 133215119,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b84354278886d46450c4886dc57317fd75b574e723fd3f35db099d58b77c4635"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study",
    "summary": "New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.",
    "url": "https://finnhub.io/api/news?id=9d033066f1282fe2483d1e26fd1f36d59fa00dafcbd8aa32ca43a0dbbfb9afa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742227500,
      "headline": "AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study",
      "id": 133325065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.",
      "url": "https://finnhub.io/api/news?id=9d033066f1282fe2483d1e26fd1f36d59fa00dafcbd8aa32ca43a0dbbfb9afa4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=bdfeb9beaa5a242e130638f4a41702c3522cf3ec9a72f80abdd96291ccf21bf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742216408,
      "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 133325066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=bdfeb9beaa5a242e130638f4a41702c3522cf3ec9a72f80abdd96291ccf21bf9"
    }
  },
  {
    "ts": null,
    "headline": "OPKO and Entera partner to develop obesity pill",
    "summary": "OPKO Health and Entera Bioare partnering to develop a once-daily pill forpatients with obesity and other disorders, the companies said onMonday. WHY IT'S IMPORTANT ...",
    "url": "https://finnhub.io/api/news?id=5c63763b0ab32e90c83586839b726eeaa3d77ccc6d41551b2fe8ee4d587323d0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742201688,
      "headline": "OPKO and Entera partner to develop obesity pill",
      "id": 133206896,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "OPKO Health and Entera Bioare partnering to develop a once-daily pill forpatients with obesity and other disorders, the companies said onMonday. WHY IT'S IMPORTANT ...",
      "url": "https://finnhub.io/api/news?id=5c63763b0ab32e90c83586839b726eeaa3d77ccc6d41551b2fe8ee4d587323d0"
    }
  }
]